Thuy Mai Van Nguyen

Imperial College London
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Despite the approval of several new treatments for patients with B-cell lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the 2 most common B-cell lymphoma subtypes, accounting for ∼50% of all cases. EZH2 heterozygous gain-of-function somatic driver mutations are frequently found in germinal center B-cell DLBCLs and FLs. An EZH2 inhibitor has shown durable responses in patients with relapsed or refractory FL, however a considerable fraction of the patients did not show an objective response. To identify alternative therapeutic strategies, we performed CRISPR/Cas9 knockout screens in B-cell lymphoma cells treated with or without an EZH2 inhibitor. This led to the identification of the histone methyltransferase DOT1L as a potential therapeutic target. Specifically, we showed that an EZH2 inhibitor synergizes with a DOT1L inhibitor in a panel of B-cell lymphoma cell lines regardless of the EZH2 mutation status. Mechanistically, we demonstrated that the 2 inhibitors cooperatively suppress DOT1L-regulated cell cycle genes, upregulate genes involved in interferon signaling, including antigen presenting genes, and ultimately drive B-cell differentiation by derepressing EZH2-regulated plasma cell signature genes. Furthermore, we demonstrated the effectiveness of this epigenetic combination strategy in a xenograft model, which led to significant abrogation of tumor growth. Together, our studies provide preclinical proof-of-concept for an epigenetic combination therapy to overcome resistance and improve durability of response for the treatment of B-cell lymphoma, warranting clinical investigation and illustrating an important convergent role of EZH2 and DOT1L in B-cell lymphomagenesis.

Year:

2025

Resistance to endocrine therapies (ET) is common in estrogen receptor (ER)–positive breast cancer, and most relapsed patients die with ET-resistant disease. Although genetic mutations provide explanations for some relapses, mechanisms of resistance remain undefined in many cases. Drug-induced epigenetic reprogramming has been shown to provide possible routes to resistance. By analyzing histone H3 lysine 27 acetylation profiles and transcriptional reprogramming in models of ET resistance, we discovered that selective ER degraders, such as fulvestrant, promote expression of vestigial-like 1 ( VGLL1 ), a coactivator for TEF-1 and AbaA domain (TEAD) transcription factors. VGLL1, acting via TEADs, promoted the expression of genes that drive the growth of fulvestrant-resistant breast cancer cells. Pharmacological disruption of VGLL1–TEAD4 interaction inhibited VGLL1/TEAD-induced transcriptional programs to prevent the growth of resistant cells. EGFR was among the VGLL1/TEAD-regulated genes, and VGLL1-directed EGFR upregulation sensitized fulvestrant-resistant breast cancer cells to EGFR inhibitors. Taken together, these findings identify VGLL1 as a transcriptional driver in ET resistance and advance therapeutic possibilities for relapsed ER + breast cancer patients. Significance: Transcriptional reprogramming mediated by the upregulation of the TEAD coactivator VGLL1 confers resistance to estrogen receptor degraders in breast cancer but provides alternative therapeutic options for this clinically important patient group.

Year:

2024

Current treatments for KRAS -mutant colorectal cancers are often limited by cellular plasticity and rewiring responses. Here we describe a promising therapeutic strategy that simultaneously targets epigenetic and oncogenic signals. Specifically, we show that inhibitors of histone methyltransferase, EZH2, synergize with various rat sarcoma virus (RAS) pathway inhibitors and promote dramatic tumor regression in vivo . Together these agents cooperatively suppress Wingless and Int-1 (WNT)-driven transcription and drive colorectal cancers into a more differentiated cell state by inducing the Groucho/transducin-like enhancer corepressor, TLE4 , along with a network of WNT pathway inhibitors and intestinal differentiation proteins. However, these agents also induce the proapoptotic protein BCL2 modifying factor (BMF), which subsequently kills these more differentiated cells. Accordingly, cell death can be prevented by activating β-catenin, by blocking differentiation, or by ablating BMF expression. Collectively, these studies reveal a new therapeutic approach for treating KRAS- mutant colorectal cancers and illustrate a critical convergence of EZH2 and RAS on oncogenic WNT signals, intestinal differentiation, and apoptosis. Significance: Combined EZH2 and RAS pathway inhibitors kill KRAS- mutant colorectal cancer cells and promote durable tumor regression in vivo . These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.

Year:

2024

Collaborators (19)

Sandro Santagata

Brigham and Women's Hospital

UNITED STATES
View details

Raoul Charles Coombes

Professor of Medical Oncology

Imperial College London

UNITED KINGDOM
View details

Alyssa Nicholls

University of Cambridge

UNITED KINGDOM
View details

Kimmie Ng

Associate Professor of Medicine, Harvard Medical School

Dana-Farber Cancer Institute

UNITED STATES
View details

Wendy Béguelin

Assistant Professor

NYU School of Medicine

UNITED STATES
View details

Simak Ali

Imperial College London

UNITED KINGDOM
View details

Kristian Helin

CEO, Professor

Institute of Cancer Research

UNITED KINGDOM
View details

Giancarlo Pruneri

University of Milan

ITALY
View details

Karen Cichowski

Professor

Brigham and Women's Hospital

UNITED STATES
View details

Alan Melcher

Professor of Translational Immunotherapy

Institute of Cancer Research

UNITED KINGDOM
View details

Elgene Lim

Clinical Academic/Professor of Medicine

University of New South Wales

AUSTRALIA
View details

Luca Magnani

Docenti

University of Milan

ITALY
View details

Heloisa Helena Milioli

University of New South Wales

AUSTRALIA
View details

Naiara Perurena

Group Leader

Instituto de Investigación Sanitaria Aragón

SPAIN
View details

Owen J. Sansom

Director

Cancer Research UK Beatson Institute

UNITED KINGDOM
View details

Laki Buluwela

Professor of Cancer Medicine

Imperial College London

UNITED KINGDOM
View details

Emad A Rakha

Professor

University of Nottingham

UNITED KINGDOM
View details

Carolina Gemma

Imperial College London

UNITED KINGDOM
View details

Ari M. Melnick

Director

Josep Carreras Leukaemia Research Institute

SPAIN
View details